35591-10-7 Usage
Uses
Used in Pharmaceutical Development:
(S)-3-(3,4-bis(benzyloxy)phenyl)-2-(benzyloxycarbonylamino)propanoic acid is used as a key intermediate in the synthesis of various pharmaceuticals due to its potential biological activity and unique structural features. Its complex composition allows for the creation of new drugs with specific therapeutic properties.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (S)-3-(3,4-bis(benzyloxy)phenyl)-2-(benzyloxycarbonylamino)propanoic acid serves as a valuable compound for studying the relationship between chemical structure and biological activity. This understanding can lead to the design of more effective and targeted therapeutic agents.
Used in Chemical Synthesis:
(S)-3-(3,4-bis(benzyloxy)phenyl)-2-(benzyloxycarbonylamino)propanoic acid is utilized as a building block in the synthesis of more complex organic molecules, particularly those with potential applications in the pharmaceutical and chemical industries. Its versatile structure allows for further functionalization and modification to create a wide range of products.
Used in Drug Delivery Systems:
Similar to other complex organic compounds, (S)-3-(3,4-bis(benzyloxy)phenyl)-2-(benzyloxycarbonylamino)propanoic acid may be employed in the development of novel drug delivery systems. These systems could improve the bioavailability, targeting, and overall efficacy of pharmaceuticals by encapsulating or conjugating the active compound for controlled release or specific targeting to disease sites.
Check Digit Verification of cas no
The CAS Registry Mumber 35591-10-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,5,9 and 1 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 35591-10:
(7*3)+(6*5)+(5*5)+(4*9)+(3*1)+(2*1)+(1*0)=117
117 % 10 = 7
So 35591-10-7 is a valid CAS Registry Number.
35591-10-7Relevant academic research and scientific papers
Carbidopa and L-Dopa Prodrugs and Methods of Use
-
, (2019/08/02)
The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising admini
GLYCOAMINO ACID AND USE THEREOF
-
, (2017/01/26)
An object of the present invention is to provide an amino acid precursor which shows improvement in the properties (particularly water-solubility, stability in water, bitter taste etc.) of amino acid, and can be converted to amino acid in vivo etc. The present invention relates to a compound for an amino acid precursor, which is a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
Design, synthesis and biological evaluation of l-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease
Zhou, Tao,Hider, Robert C.,Jenner, Peter,Campbell, Bruce,Hobbs, Christopher J.,Rose, Sarah,Jairaj, Mark,Tayarani-Binazir, Kayhan A.,Syme, Alexander
experimental part, p. 4035 - 4042 (2010/10/02)
A range of amide derivatives of l-dopa were synthesized and investigated for their pharmacological activity and their ability to be converted to l-dopa using the unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rat, as an experimental model of Parkinson's
